[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632435":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":25,"locations":25,"responsibleParty":30,"collaborators":25,"id":32,"slug":33,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":25,"eligibilityCriteria":38,"healthyVolunteers":39,"sex":40,"minAge":41,"maxAge":42,"enrollmentInfo":43,"targetDuration":25,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":25,"overallStatus":52,"whyStopped":25,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":25},{"fullName":5,"class":6},"Dong-A ST Co., Ltd.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence A","EXPERIMENTAL","Period 1(DA-5230-R), Period 2(DA-5230)",[13,14],"Drug: DA-5230","Drug: DA-5230-R",{"label":16,"type":10,"description":17,"interventionNames":18},"Sequence B","Period 1(DA-5230), Period 2(DA-5230-R)",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","DA-5230","Test drug",[9,16],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"DA-5230-R","Reference drug",[9,16],{"type":31,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100632435","phase-1-a-study-to-evaluate-the-bioequivalence-of-da-5230-compared-to-da-5230-r-100632435",false,"NCT07513649","A Study to Evaluate the Bioequivalence of DA-5230 Compared to DA-5230-R","An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Bioequivalence of DA-5230 With DA-5230-R in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy participants aged 19 to 55 years at the time of screening visit\n* Body weight equal to or greater than 50kg (Female 45kg) and Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n\nExclusion Criteria:\n\n* Participants who have received an investigational product in another clinical trial or a bioequivalence study within 6 months prior to the first dosing\n* Participants deemed unsuitable for participation in this clinical trial by the investigator",true,"ALL","19 Years","55 Years",{"count":44,"type":45},60,"ESTIMATED","INTERVENTIONAL",[48],"PHASE1","A study to evaluate the bioequivalence of DA-5230 compared to DA-5230-R",[51],"Healthy Adult Participants","NOT_YET_RECRUITING","2026-03-31",{"date":55,"type":56},"2026-04-07","ACTUAL",{"date":58,"type":45},"2026-04",{"date":60,"type":45},"2026-05",{"name":5,"class":6}]